Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer

Ruihong Dong; Ting Ding; Zhengyu Li

doi:10.3389/fphar.2023.1164395

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer

Front Pharmacol. 2023 Jun 23:14:1164395. doi: 10.3389/fphar.2023.1164395. eCollection 2023.

Authors

Ruihong Dong^{1

2}, Ting Ding^{1

2}, Zhengyu Li^{1

2}

Affiliations

¹ Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, China.
² Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China.

Abstract

Ovarian cancer is one of the most common reproductive system tumors. The incidence of ovarian cancer in China is on the rise. Poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) is a DNA repair enzyme associated with DNA damage repair. PARPi takes PARP as a target to kill tumor cells, especially for tumors with homologous recombination (HR) dysfunction. Currently, PARPi has been widely used in clinical practice, mainly for the maintenance of advanced ovarian epithelial cancer. The intrinsic or acquired drug resistance of PARPi has gradually become an important clinical problem with the wide application of PARPi. This review summarizes the mechanisms of PARPi resistance and the current progress on PARPi-based combination strategies.

Keywords: combination therapy; drug resistance; mechanism; ovarian cancer; poly ADP-ribose polymerase inhibitors.

Publication types

Review